The Post-Finasteride Syndrome Foundation’s primary mission is to facilitate research on the characterization, underlying biologic mechanisms, and potential treatments of post-finasteride syndrome (PFS). Other goals include generating public awareness of PFS, and providing support for patients suffering from the condition.
Adverse drug reaction reports worldwide
PFS research studies published
Known suicides worldwide
Doctors & researchers speaking out
Nations warning of PFS
July 14, 2021 Dear Friends: The first study to consider and demonstrate gene expression differences as a potential etiology of the sexual dysfunction experienced by PFS patients has been published by a research team at Baylor College of Medicine (BCM). In all, the PFS patients had 1,446 significantly over-expressed (upregulated) and 2,318 significantly under-expressed (downregulated) […]
June 29, 2021 Dear Friends: The PFS Foundation has launched a new section of its website to house documents from the US Propecia litigation unsealed by court order earlier this year. Part A of our Propecia Litigation Library (Paper Trail), contains 479 pages of such documents, along with 125 pages of related content, including Merck’s […]
April 13, 2021 Dear Friends: Phase V of the PFS Foundation-sponsored research at the University of Milano (UniMi) has found that finasteride, a 5-alpha reductase (5α-R) inhibitor, also inhibits phenylethanolamine N-methyltransferase (PNMT), an enzyme found primarily in the adrenal gland, which in turn may play a role in producing some of the condition’s most common […]
February 1, 2021 Dear Friends: The PFS Foundation has filed supplements to its FDA Citizen Petition requesting that the agency “immediately require withdrawal of marketing approval for Propecia…because the risk of serious injury from the drug outweighs its limited benefits.” The two supplements were filed Dec. 1, 2020 and posted publicly late last month on […]
January 20, 2021 Dear Friends: The nation that gave us such wise figures as Mahatma Gandhi, Srinivasa Ramanujan and Anandibai Joshi just got a bit wiser. With respect to PFS, that is. Now, speakers of the world’s third most popular language can read all about post-finasteride syndrome (aka “पोस्ट-फ़ाइस्टरसाइड सिंड्रोम”) in their native tongue. To […]
Men under the age of 40 who use finasteride for alopecia are at risk for suicide if they develop persistent sexual adverse effects and insomnia.
An important pattern of symptoms was common among all cases who committed suicide in the setting of finasteride use: insomnia and persistent sexual dysfunction after medication discontinuation. Insomnia and fatigue/tiredness were some of the most debilitating symptoms… Men under 40 years of age who use finasteride for alopecia are at risk of suicide if they develop persistent sexual adverse effects and insomnia.
—Finasteride and Suicide: A Postmarketing Case Series: Dermatology, January 14, 2020
Two subjects—eight percent—committed suicide during or after the study.
While the sexual side effects of 5ARIs are well known, there may be persistent genitourinary, physical, psycho-cognitive, anti-androgenic and penile vascular changes after 5ARI discontinuation. Use of 5ARIs for treatment of AGA may lead to persistent sexual, genitourinary, physical, psycho-cognitive, and anti-androgenic sequelae even after cessation of 5ARI therapy… Two subjects (8%) committed suicide during or after the study.
—Penile vascular abnormalities in young men with persistent side effects after finasteride use for the treatment of androgenic alopecia: Translational Andrology and Urology, April 2020
Health care professionals should…conduct a full evaluation and a…risk-benefit assessment for patients before each prescription of finasteride.
As prescribers, our primary duty is to do no harm. Health care professionals should keep themselves abreast of these potential signals and, accordingly, conduct a full evaluation and a detailed, personalized risk-benefit assessment for patients before each prescription of finasteride.
—Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia: JAMA Dermatology, November 2020
This drug for young men must be taken off the market.
As of 2018, 15,000 cases of adverse reactions to finasteride were reported to the WHO—which is a huge number to begin with. And the interesting thing is that the average age of this group was 32 to 34 years old… This drug for young men must be taken off the market.
—Documentary on German network NDR titled Side Effects of Finasteride Are Underestimated: January 25, 2021